HONG KONG--(Marketwire - Jun 8, 2012) - Today, [ www.EquityLeader.com ] introduced research coverage of Regeneron Pharmaceuticals Inc (NASDAQ: [ REGN ]) and Elan Corporation, plc (ADR) (NYSE: [ ELN ]). Full research reports are available to readers at: [ www.EquityLeader.com/index.php?sm1=REGN&sm2=ELN ].

With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Equity Leader has decided to cover Regeneron Pharmaceuticals Inc for its current position within the healthcare industry. Regeneron Pharmaceuticals Inc (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. A copy of this report detailing Regeneron Pharmaceuticals Inc (NASDAQ: [ REGN ]) is available at: [ www.EquityLeader.com/index.php?sm1=REGN ].

Equity Leader is also taking note of Elan Corporation, plc (ADR) for its changing role within the healthcare industry. Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Elan is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. To download free research on Elan Corporation, plc (ADR) (NYSE: [ ELN ]) investors may visit: [ www.EquityLeader.com/index.php?sm2=ELN ].

About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.